Related Experiment Video
Updated: Mar 22, 2026
06:30
Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
Published on: September 11, 2018
8.4K
Neural modulation for hypertension and heart failure.
S Smith1, P Rossignol2, S Willis1
1The Ohio State University Wexner Medical Center, Department of Internal Medicine and Division of Cardiology, Columbus, OH, USA.
International Journal of Cardiology
|April 17, 2016
Summary
Neuromodulation offers new hope for resistant hypertension and heart failure. Exploring therapies like renal denervation and vagal stimulation may improve outcomes when combined with existing treatments.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Medical Technology
Background:
- Hypertension (HTN) and heart failure (HF) significantly increase global morbidity and mortality.
- Sub-optimal HTN treatment elevates risks for stroke, renal failure, and HF.
- Outcomes for HF patients remain poor despite current pharmacological and device therapies.
Purpose of the Study:
- To review the evidence for neuromodulation in treating resistant HTN and HF.
- To explore synergistic effects of neuromodulation with existing drug and device therapies.
- To outline strategies for improving future neuromodulation trial success.
Main Methods:
- Review of current evidence on neuromodulation techniques.
- Analysis of neuromodulation in relation to established treatments (pharmacologic, CRT, ICDs).
- Discussion of lessons learned from recent neuromodulation trials.
Main Results:
- Neuromodulation, including renal denervation, baro-reflex modulation, and vagal stimulation, shows potential for resistant HTN and HF.
- Potential for synergistic effects exists when combining neuromodulation with conventional therapies.
- Insights gained from past trials can guide future research and improve success rates.
Conclusions:
- Neuromodulation represents a promising frontier for managing treatment-resistant hypertension and heart failure.
- Further research and optimized trial designs are crucial for realizing the full potential of these therapies.
- Combining neuromodulation with existing treatments may offer enhanced therapeutic benefits for patients.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:18Neural Regulation of Blood Pressure
8.2K
The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
8.2K
01:29Heart Failure II: Pathophysiology
1.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
01:30Heart Failure V: Medical Management
508
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
508
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K